Comprehensive Add on Study in Japan
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 574 participants.
Also called NCT01204294
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 574 participants
- Registry
-
NCT01204294
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01204294. Randomized; no masking; primary purpose treatment. Start 2010-09 (registry gives no type); primary completion 2012-01 (actual). Results posted on 2013-01-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comprehensive Add on Study in Japan
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Linagliptin
- Intervention (Drug)
- Linagliptin
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Linagliptin
- Intervention (Drug)
- Linagliptin
- Intervention (Drug)
- Linagliptin
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01204294- Content hash
e59ecfec0e9e40fb633b02bc87308442e6163f4958b37e00620fbda593479e8b